On 28 April 2026, the SGLT2 HYPE consortium gathered in Hamburg for the project’s 2nd General Assembly Meeting, bringing together partners from across Europe to discuss progress, achievements, challenges, and next steps of this Horizon Europe-funded clinical trial.
The meeting opened with a keynote session on the latest hypertension guidelines and remaining unmet clinical needs, followed by an overview of the project’s achievements so far and the outlook for 2026. Throughout the day, consortium partners presented updates from all major work packages, covering topics such as:
- Clinical trial implementation and recruitment
- eHealth and patient involvement
- Biobanking and biomarker analyses
- Statistical analyses and health economics
- Monitoring, stakeholder engagement, dissemination, and project management
The discussions highlighted the strong progress achieved across the consortium and the collaborative efforts driving the project forward. Special attention was given to patient-centred innovation, data quality, stakeholder engagement, and the long-term clinical and societal impact of the SGLT2 HYPE trial.
A sincere thank you to all partners, Scientific & Ethics Advisory Board members, our Project Officer, speakers, and contributors for the productive discussions and continued commitment to improving hypertension care across Europe.
Together, we continue working towards a future of better cardiovascular and renal health for millions of patients affected by hypertension.
